Pharmaceuticals - Diversified

Page 3

Human Genome Sciences Inc Responds To Glaxosmithkline Plc's Extension Of Unsolicited Tender Offer

Friday, 29 Jun 2012 08:56am EDT

Human Genome Sciences Inc (HGS) announced statement regarding the extension by GlaxoSmithKline plc (GSK) of unsolicited tender offer to acquire all the outstanding common shares of HGS at a price of $13.00 per share in cash and GSK’s statement that approximately 375,526 shares of HGS common stock have been tendered into their offer. HGS noted that less than 1% of its shares outstanding tendered into the GSK offer. The HGS Board of Directors has rejected GSK’s unsolicited $13.00 per share tender offer after determining, in consultation with financial and legal advisors, that the GSK offer price is inadequate and does not reflect the value inherent in HGS. As previously announced, the Board has authorized the exploration of strategic alternatives in the interests of stockholders, including a potential sale of the Company, and has set a bid date of July 16, 2012 for the submission of definitive proposals to acquire all common shares of HGS. This process continues to be active and fully underway. Although HGS continues to welcome GSK's participation, GSK has twice declined to enter the process. The HGS Board of Directors recommends that HGS stockholders reject GSK’s tender offer and not tender any of their shares to GSK. Goldman, Sachs & Co. and Credit Suisse Securities (USA) LLC are serving as financial advisors to HGS, and Skadden, Arps, Slate, Meagher & Flom LLP and DLA Piper LLP (US) are serving as legal counsel.

Glaxosmithkline Plc Sets July 20 For Expiration Of Tender Offer To Acquire Human Genome Sciences Inc

Friday, 29 Jun 2012 07:00am EDT

Glaxosmithkline Plc announced it has extended its tender offer to acquire all of the outstanding shares of Human Genome Sciences for USD13.00 per share in cash to 5:00 p.m New York City time on July 20, 2012. GSK's tender offer will expire after July 16, the deadline set by HGS for submission of definitive acquisition proposals in its strategic alternatives review process which began on April 19 after GSK made a private proposal on April 11. GSK believes the three months that will have passed since the start of this process is more than adequate time for the HGS Board to bring it to completion. Extension of the tender offer to July 20 will provide HGS shareholders the opportunity to evaluate the outcome of the HGS Board's process relative to GSK's offer. Based on circumstances at that time, GSK will consider all available options regarding its offer but can make no assurance that the tender offer will be further extended. The closing of the tender offer is subject to the terms and conditions detailed in the amended tender offer documents as filed on Schedule TO with the SEC on May 10 and May 23. Except for the extension of the tender offer expiration date, all other terms and conditions of the offer remain unchanged. The tender offer was previously scheduled to expire at 5:00 p.m. New York City time, on June 29. Lazard and Morgan Stanley are acting as financial advisors to GSK and Cleary Gottlieb Steen & Hamilton and Wachtell, Lipton, Rosen & Katz are providing legal advice.

Novartis AG, Four Others Weigh Amylin Pharmaceuticals Inc Final Bids-Reuters

Tuesday, 26 Jun 2012 12:37pm EDT

Reuters reported that five pharmaceutical giants including Novartis AG and Sanofi SA remain in the running for Amylin Pharmaceuticals Inc, as the auction of the diabetes drug maker with a market value of $4.5 billion enters the last leg, according to people familiar with the matter. Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc also remain involved, the people said. Final bids are expected starting the end of this week, they said. All of the potential acquirers declined to comment. Amylin was not immediately available for comment.

Sanofi SA, Four Others Weigh Amylin Pharmaceuticals Inc Final Bids-Reuters

Tuesday, 26 Jun 2012 12:37pm EDT

Reuters reported that five pharmaceutical giants including Novartis AG and Sanofi SA remain in the running for Amylin Pharmaceuticals Inc, as the auction of the diabetes drug maker with a market value of $4.5 billion enters the last leg, according to people familiar with the matter. Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc also remain involved, the people said. Final bids are expected starting the end of this week, they said. All of the potential acquirers declined to comment. Amylin was not immediately available for comment.

Bristol-Myers Squibb Co, Four Others Weigh Amylin Pharmaceuticals Inc Final Bids-Reuters

Tuesday, 26 Jun 2012 12:37pm EDT

Reuters reported that five pharmaceutical giants including Novartis AG and Sanofi SA remain in the running for Amylin Pharmaceuticals Inc, as the auction of the diabetes drug maker with a market value of $4.5 billion enters the last leg, according to people familiar with the matter. Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc also remain involved, the people said. Final bids are expected starting the end of this week, they said. All of the potential acquirers declined to comment. Amylin was not immediately available for comment.

Merck & Co Inc, Four Others Weigh Amylin Pharmaceuticals Inc Final Bids-Reuters

Tuesday, 26 Jun 2012 12:37pm EDT

Reuters reported that five pharmaceutical giants including Novartis AG and Sanofi SA remain in the running for Amylin Pharmaceuticals Inc, as the auction of the diabetes drug maker with a market value of $4.5 billion enters the last leg, according to people familiar with the matter. Bristol-Myers Squibb Co, AstraZeneca Plc, Merck & Co Inc also remain involved, the people said. Final bids are expected starting the end of this week, they said. All of the potential acquirers declined to comment. Amylin was not immediately available for comment.

Farmstandart OAO Completes Acquisition Of 50.1% Stake In Bigpearl Trading Limited

Monday, 25 Jun 2012 08:00pm EDT

Farmstandart OAO announces that it has completed the acquisition of a 50.1% stake in Bigpearl Trading Limited. Further details were not disclosed.

Markets

  • Sectors
  • U.S.
  • Europe
  • Asia

Sector Summary

Analyst Research

Report Title Price
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.